White House Announcement made on October 22, 2019
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of diseases with unmet medical need, including Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that Sharon H. Hrynkow, Ph.D., its Chief Scientific Officer and Senior Vice President for Medical Affairs, has been appointed to the President’s Council of Advisors on Science and Technology (PCAST). On October 22, President Donald J. Trump signed an executive order re-chartering PCAST and announced the first seven members, including Dr. Hrynkow.
Dr. Hrynkow, a neuroscientist by training, has served in executive leadership roles at the National Institutes of Health, as the inaugural President of the Global Virus Network, a non-profit organization, and as Senior Science Advisor at the Department of State. Dr. Hrynkow leads the Cyclo Therapeutics, Inc. clinical and scientific programs developing the company’s drug, Trappsol® Cyclo™, for treatment of Niemann-Pick Disease Type C, a rare and fatal disease in children, and for Alzheimer’s Disease. She is Co-Chair of the Company’s Scientific Advisory Board.
A total of 16 members are expected to be appointed to PCAST. Dr. Kelvin Droegemeier, Director of The White House Office of Science and Technology, will chair the Council. See the full announcement HERE.
“Under this Administration, science and technology in America continues to advance by leaps and bounds. PCAST will be critical to our continued efforts, with each member bringing a unique perspective to the table. By convening a diverse group of our Nation’s foremost leaders across a broad range of fields, we can leverage the full innovation ecosystem, solve some of the Nation’s greatest challenges, and ensure America’s science and technology leadership for generations to come,” said Dr. Droegemeier.
“Advances in science and technology are major drivers of US economic growth and they contribute to our nation’s security,” said Dr. Hrynkow. “I am delighted to serve on PCAST to work with colleagues across many disciplines to find solutions to critical science and technology challenges facing our nation.”
“We are all very proud to see Dr. Hrynkow appointed to PCAST, and we know that she will serve with distinction,” said Company Chairman and CEO, N. Scott Fine.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
PCAST was launched by Executive Order in 2001, formalizing a process that had been in place through many previous Administrations to advise the President on matters involving science, technology, education, and innovation policy. The Council provides the President with scientific and technical information that is needed to inform public policy relating to the American economy, the American worker, national and homeland security, and other topics. The Council includes distinguished individuals from sectors outside of the Federal Government and represents diverse perspectives and expertise in science, technology, education and innovation.
Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
RedChip Companies, Inc.
Source: Cyclo Therapeutics, Inc.